TROPION-Breast01: NCT05104866: Phase 3: Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer, treated With 1-2 Prior LOT
First Posted 2021-11-03 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation ESMO 2023 (Annals of Oncology) abstract (LBA11) LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial October 2023 Click here for details AACR 2024 (Cancer Research) abstract (GS02-01) Ab
Dec 15, 2025